Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy

Alexander W. Wyatt, K.N. Chi, Joanna Vergidis et al.|Annals of Oncology|2016

Cited by 6